Logo of gutGutVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
Gut. 2001 Jan; 48(1): 132–135.
PMCID: PMC1728175

Bacteria as the cause of ulcerative colitis

Full Text

The Full Text of this article is available as a PDF (121K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Hunt RH, Lam SK. Helicobacter pylori: from art to a science. J Gastroenterol Hepatol. 1998 Jan;13(1):21–28. [PubMed]
  • Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet. 1977 Oct 29;2(8044):892–895. [PubMed]
  • Sutherland LR, May GR, Shaffer EA. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med. 1993 Apr 1;118(7):540–549. [PubMed]
  • Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet. 1974 Jun 1;1(7866):1067–1070. [PubMed]
  • Sanderson JD, Moss MT, Tizard ML, Hermon-Taylor J. Mycobacterium paratuberculosis DNA in Crohn's disease tissue. Gut. 1992 Jul;33(7):890–896. [PMC free article] [PubMed]
  • Darfeuille-Michaud A, Neut C, Barnich N, Lederman E, Di Martino P, Desreumaux P, Gambiez L, Joly B, Cortot A, Colombel JF. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology. 1998 Dec;115(6):1405–1413. [PubMed]
  • Rhodes JM. Unifying hypothesis for inflammatory bowel disease and associated colon cancer: sticking the pieces together with sugar. Lancet. 1996 Jan 6;347(8993):40–44. [PubMed]
  • Bamba T, Matsuda H, Endo M, Fujiyama Y. The pathogenic role of Bacteroides vulgatus in patients with ulcerative colitis. J Gastroenterol. 1995 Nov;30 (Suppl 8):45–47. [PubMed]
  • Nataro JP, Kaper JB. Diarrheagenic Escherichia coli. Clin Microbiol Rev. 1998 Jan;11(1):142–201. [PMC free article] [PubMed]
  • Walmsley RS, Anthony A, Sim R, Pounder RE, Wakefield AJ. Absence of Escherichia coli, Listeria monocytogenes, and Klebsiella pneumoniae antigens within inflammatory bowel disease tissues. J Clin Pathol. 1998 Sep;51(9):657–661. [PMC free article] [PubMed]
  • Kallinowski F, Wassmer A, Hofmann MA, Harmsen D, Heesemann J, Karch H, Herfarth C, Buhr HJ. Prevalence of enteropathogenic bacteria in surgically treated chronic inflammatory bowel disease. Hepatogastroenterology. 1998 Sep-Oct;45(23):1552–1558. [PubMed]
  • Burke DA, Axon AT. Ulcerative colitis and Escherichia coli with adhesive properties. J Clin Pathol. 1987 Jul;40(7):782–786. [PMC free article] [PubMed]
  • Burke DA, Axon AT. Adhesive Escherichia coli in inflammatory bowel disease and infective diarrhoea. BMJ. 1988 Jul 9;297(6641):102–104. [PMC free article] [PubMed]
  • Schultsz C, Moussa M, van Ketel R, Tytgat GN, Dankert J. Frequency of pathogenic and enteroadherent Escherichia coli in patients with inflammatory bowel disease and controls. J Clin Pathol. 1997 Jul;50(7):573–579. [PMC free article] [PubMed]
  • von Wulffen H, Rüssmann H, Karch H, Meyer T, Bitzan M, Kohrt TC, Aleksic S. Verocytotoxin-producing Escherichia coli O2:H5 isolated from patients with ulcerative colitis. Lancet. 1989 Jun 24;1(8652):1449–1450. [PubMed]
  • Schultsz C, Van Den Berg FM, Ten Kate FW, Tytgat GN, Dankert J. The intestinal mucus layer from patients with inflammatory bowel disease harbors high numbers of bacteria compared with controls. Gastroenterology. 1999 Nov;117(5):1089–1097. [PubMed]
  • Cummings JH. Short chain fatty acids in the human colon. Gut. 1981 Sep;22(9):763–779. [PMC free article] [PubMed]
  • Roediger WE. The colonic epithelium in ulcerative colitis: an energy-deficiency disease? Lancet. 1980 Oct 4;2(8197):712–715. [PubMed]
  • Pitcher MC, Cummings JH. Hydrogen sulphide: a bacterial toxin in ulcerative colitis? Gut. 1996 Jul;39(1):1–4. [PMC free article] [PubMed]
  • Marcus R, Watt J. Ulcerative disease of the colon in laboratory animals induced by pepsin inhibitors. Gastroenterology. 1974 Sep;67(3):473–483. [PubMed]
  • Onderdonk AB, Bronson R, Cisneros R. Comparison of Bacteroides vulgatus strains in the enhancement of experimental ulcerative colitis. Infect Immun. 1987 Mar;55(3):835–836. [PMC free article] [PubMed]
  • Rath HC, Ikeda JS, Linde HJ, Schölmerich J, Wilson KH, Sartor RB. Varying cecal bacterial loads influences colitis and gastritis in HLA-B27 transgenic rats. Gastroenterology. 1999 Feb;116(2):310–319. [PubMed]
  • Ehrhardt RO, Lúdvíksson BR, Gray B, Neurath M, Strober W. Induction and prevention of colonic inflammation in IL-2-deficient mice. J Immunol. 1997 Jan 15;158(2):566–573. [PubMed]
  • Kühn R, Löhler J, Rennick D, Rajewsky K, Müller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 1993 Oct 22;75(2):263–274. [PubMed]
  • Dickinson RJ, O'Connor HJ, Pinder I, Hamilton I, Johnston D, Axon AT. Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut. 1985 Dec;26(12):1380–1384. [PMC free article] [PubMed]
  • Chapman RW, Selby WS, Jewell DP. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut. 1986 Oct;27(10):1210–1212. [PMC free article] [PubMed]
  • Burke DA, Axon AT, Clayden SA, Dixon MF, Johnston D, Lacey RW. The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 1990 Apr;4(2):123–129. [PubMed]
  • Mantzaris GJ, Hatzis A, Kontogiannis P, Triadaphyllou G. Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am J Gastroenterol. 1994 Jan;89(1):43–46. [PubMed]
  • Gionchetti P, Rizzello F, Ferrieri A, Venturi A, Brignola C, Ferretti M, Peruzzo S, Miglioli M, Campieri M. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. Dig Dis Sci. 1999 Jun;44(6):1220–1221. [PubMed]
  • Mantzaris GJ, Archavlis E, Christoforidis P, Kourtessas D, Amberiadis P, Florakis N, Petraki K, Spiliadi C, Triantafyllou G. A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis. Am J Gastroenterol. 1997 Mar;92(3):454–456. [PubMed]
  • Turunen UM, Färkkilä MA, Hakala K, Seppälä K, Sivonen A, Ogren M, Vuoristo M, Valtonen VV, Miettinen TA. Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology. 1998 Nov;115(5):1072–1078. [PubMed]
  • Present DH. Ciprofloxacin as a treatment for ulcerative colitis-not yet. Gastroenterology. 1998 Nov;115(5):1289–1291. [PubMed]
  • Simon GL, Gorbach SL. Intestinal flora in health and disease. Gastroenterology. 1984 Jan;86(1):174–193. [PubMed]
  • Weiner HL, van Rees EP. Mucosal tolerance. Immunol Lett. 1999 Jun 15;69(1):3–4. [PubMed]
  • Duchmann R, Neurath MF, Meyer zum Büschenfelde KH. Responses to self and non-self intestinal microflora in health and inflammatory bowel disease. Res Immunol. 1997 Oct-Dec;148(8-9):589–594. [PubMed]
  • Garside P, Mowat AM, Khoruts A. Oral tolerance in disease. Gut. 1999 Jan;44(1):137–142. [PMC free article] [PubMed]
  • Inobe J, Slavin AJ, Komagata Y, Chen Y, Liu L, Weiner HL. IL-4 is a differentiation factor for transforming growth factor-beta secreting Th3 cells and oral administration of IL-4 enhances oral tolerance in experimental allergic encephalomyelitis. Eur J Immunol. 1998 Sep;28(9):2780–2790. [PubMed]
  • Lebman DA, Edmiston JS. The role of TGF-beta in growth, differentiation, and maturation of B lymphocytes. Microbes Infect. 1999 Dec;1(15):1297–1304. [PubMed]
  • Duchmann R, Schmitt E, Knolle P, Meyer zum Büschenfelde KH, Neurath M. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur J Immunol. 1996 Apr;26(4):934–938. [PubMed]
  • Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, Meyer zum Büschenfelde KH. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD) Clin Exp Immunol. 1995 Dec;102(3):448–455. [PMC free article] [PubMed]
  • Duchmann R, May E, Heike M, Knolle P, Neurath M, Meyer zum Büschenfelde KH. T cell specificity and cross reactivity towards enterobacteria, bacteroides, bifidobacterium, and antigens from resident intestinal flora in humans. Gut. 1999 Jun;44(6):812–818. [PMC free article] [PubMed]
  • Macpherson A, Khoo UY, Forgacs I, Philpott-Howard J, Bjarnason I. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut. 1996 Mar;38(3):365–375. [PMC free article] [PubMed]
  • Hollander D. Permeability in Crohn's disease: altered barrier functions in healthy relatives? Gastroenterology. 1993 Jun;104(6):1848–1851. [PubMed]
  • Satsangi J, Jewell DP, Rosenberg WM, Bell JI. Genetics of inflammatory bowel disease. Gut. 1994 May;35(5):696–700. [PMC free article] [PubMed]
  • Campieri M, Gionchetti P. Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeutic alternative? Gastroenterology. 1999 May;116(5):1246–1249. [PubMed]
  • Fabia R, Ar'Rajab A, Johansson ML, Andersson R, Willén R, Jeppsson B, Molin G, Bengmark S. Impairment of bacterial flora in human ulcerative colitis and experimental colitis in the rat. Digestion. 1993;54(4):248–255. [PubMed]
  • Malin M, Suomalainen H, Saxelin M, Isolauri E. Promotion of IgA immune response in patients with Crohn's disease by oral bacteriotherapy with Lactobacillus GG. Ann Nutr Metab. 1996;40(3):137–145. [PubMed]
  • Fabia R, Ar'Rajab A, Johansson ML, Willén R, Andersson R, Molin G, Bengmark S. The effect of exogenous administration of Lactobacillus reuteri R2LC and oat fiber on acetic acid-induced colitis in the rat. Scand J Gastroenterol. 1993 Feb;28(2):155–162. [PubMed]
  • Mao Y, Nobaek S, Kasravi B, Adawi D, Stenram U, Molin G, Jeppsson B. The effects of Lactobacillus strains and oat fiber on methotrexate-induced enterocolitis in rats. Gastroenterology. 1996 Aug;111(2):334–344. [PubMed]
  • Madsen KL, Doyle JS, Jewell LD, Tavernini MM, Fedorak RN. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology. 1999 May;116(5):1107–1114. [PubMed]
  • Kruis W, Schütz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 1997 Oct;11(5):853–858. [PubMed]
  • Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet. 1999 Aug 21;354(9179):635–639. [PubMed]
  • Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P, Matteuzzi D, Campieri M. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther. 1999 Aug;13(8):1103–1108. [PubMed]
  • Mack DR, Michail S, Wei S, McDougall L, Hollingsworth MA. Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol. 1999 Apr;276(4 Pt 1):G941–G950. [PubMed]

Articles from Gut are provided here courtesy of BMJ Group


Save items

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...